And now,
compare us.

KidneyIntelXTM: what it is vs. what it’s not

IS IS NOT
Focused, almost exclusively, on assisting nephrologists with their chronic kidney disease patients in stages 4-5 who are transitioning to dialysis or transplant.
Provides primary care doctors with a test to risk assess rapid progressive decline in kidney function in adult patients with type 2 diabetes and chronic kidney disease stages 1-3b. This allows PCPs to identify risk early enough to improve kidney outcomes and promote and improve overall patient health.
A test that reliably predicts where each adult patient with type 2 diabetes and with chronic kidney disease stages 1-3b falls on the risk spectrum for rapid kidney disease progression (High/Intermediate/Low) and informs guideline-recommended treatment plans.
Only test that leverages the three proprietary biomarkers demonstrated to be most prognostic for chronic kidney disease progression.
Supported by multiple clinical studies, including one that demonstrated a 72% improvement in predicting those adult patients who are at high risk for progression vs current standard of care (using eGFR and UACR alone).
Supported by multiple clinical studies, it’s the only test that’s demonstrated to reliably reproduce results in risk assessing diabetic kidney disease for rapid progressive decline in kidney function.
Is seeking FDA De Novo marketing authorization – based on all of its available clinical data – to give clinicians and patients additional confidence when defining precision medicine care plans for their adult patients with type 2 diabetes and with chronic kidney disease stages 1-3b
A laboratory test for rapid progressive decline in kidney function with a national payment rate for Medicare.
Is:

Provides primary care doctors with a tool to risk assess rapid progressive decline in kidney function in adult diabetic patients and chronic kidney disease stages 1-3b. This allows PCPs to identify risk early enough to improve kidney outcomes and promote and improve overall patient health.

A test that reliably predicts where each diabetic kidney disease patient falls on the risk spectrum for rapid kidney disease progression (High/Intermediate/Low) and informs guideline-recommended treatment and therapeutic plans.

Only test that leverages the three, proprietary biomarkers demonstrated to be most prognostic for chronic kidney disease progression.

Supported by multiple clinical studies, including one that demonstrated a 72% improvement in predicting those adult patients who are at high risk for progression vs current standard of care (using eGFR and UACR alone).

Supported by multiple clinical studies, it's the only test that’s demonstrated to reliably reproduce results in risk assessing diabetic kidney disease for rapid progressive decline in kidney function.

Is seeking FDA De Novo marketing authorization – based on all of its available clinical data - to give clinicians and patients additional confidence when defining their adult diabetic kidney disease precision medicine care plans.

A laboratory test for rapid progressive decline in kidney function with a national payment rate for Medicare.

Is not:

Focused, almost exclusively, on assisting nephrologists with their chronic kidney disease patients in stages 4-5 who are transitioning to dialysis or transplant

Prognostic, not Diagnostic